The US Food and Drug Administration (FDA) last week granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumour activity, for people with hepatocellular carcinoma.
Nivolumab, an antibody that blocks the PD-1 (programmed death protein
1) receptor, was approved for people previously treated with sorafenib (Nexavar). Approval was supported by findings from the CheckMate 040 study
presented at the 2016 AASLD Liver Meeting. While response rates in this
study were not particularly high, there are few good existing options
for people with this type of cancer, especially those with recurring
Over years or decades chronic hepatitis B virus (HBV) or hepatitis C
virus (HCV) infection, heavy alcohol use, fatty liver disease and other
causes of liver injury can lead to serious liver disease including
cirrhosis and hepatocellular carcinoma (HCC), a type of primary liver
cancer. People with hepatitis B can develop HCC despite antiviral
therapy, and people with hepatitis C who have progressed to cirrhosis remain at risk for liver cancer even after being cured with direct-acting antiviral therapy.
- compensated cirrhosis
The earlier stage of
cirrhosis, during which the liver is damaged but still able to perform most of
its functions. See also ‘cirrhosis’ and ‘decompensated cirrhosis’.
- hepatocellular carcinoma (HCC)
Liver cancer. A long-term complication of chronic inflammation of the liver or cirrhosis.
type of tumour affecting the lymph nodes.
HCC is often diagnosed late and is difficult to treat, making it a
leading cause of cancer death worldwide. Sorafenib, a tyrosine kinase
inhibitor, is the standard of care for HCC that cannot be surgically
removed, but it typically extends survival by only a few months. A
similar drug, regorafenib (Stivarga), was recently approved for second-line HCC treatment, but there is an unmet need for more effective and longer-acting options.
Nivolumab is a human monoclonal antibody that interferes with PD-1, a
cell-signalling molecule on T-cells. PD-1 regulates immune responses by
suppressing excessive immune activation. Some cancers can hijack PD-1
to disable immune responses against them. By blocking PD-1, checkpoint
inhibitors like nivolumab can restore T-cell activity against cancer
"PD-1 puts a brake on immune response, and nivolumab releases the
brake," explained Bruno Sangro of Clinica Universidad de Navarra in
Pamplona, Spain, who presented findings from Checkmate 040 at last
year's Liver Meeting. Study results were also recently published in The Lancet.
This phase 1/2 trial enrolled 262 people with compensated cirrhosis
and advanced HCC whose tumours could not be surgically removed. Most
were men and the average age was 63 years. Two-thirds had previously
used sorafenib. About a quarter had HBV, another quarter had HCV and
half had neither virus. Around 70% had metastases, or spread of cancer
beyond the liver.
One part of the study included 154 people who experienced disease
progression on sorafenib or were unable to tolerate it. Overall, 14% of
this group showed some degree of response, or tumour shrinkage,
according to a Bristol-Myers Squibb press release.
Of these, 2% had complete responses and 12% had partial responses;
about another 40% had stable disease. Among the 22 participants
classified as responders, most were still responding at six months and
55% had responses lasting at least a year. Responses occurred regardless
of PD-1 expression status or HBV or HCV infection.
Treatment with nivolumab was generally safe. More than 10% of treated
participants had seriously elevated liver enzymes and 5% developed
immune-mediated hepatitis requiring corticosteroids. The major concern
with checkpoint inhibitors like nivolumab is immune-related adverse
events; the drugs work by restoring immune responses against cancer
cells, but they can also cause excessive inflammation of healthy tissue.
Nivolumab is the first immunotherapy approved for liver cancer. It is
indicated for people with HCC who were previously treated with
sorafenib. Data presented at this year's American Society of Clinical
Oncology annual meeting showed that people who had never used sorafenib
had somewhat better long-term outcomes on nivolumab, but the FDA has not
yet approved nivolumab for this group. There are no restrictions based
on PD-1 expression level. Nivolumab is administered by intravenous
infusion every two weeks until disease progression or unacceptable
Nivolumab is currently approved by the European Medicines Agency (EMA)
for treatment of advanced melanoma, non-small cell lung cancer, kidney
cancer and some types of lymphoma, but not yet for HCC. In the US it is
also approved for thyroid cancer.
Continued approval of nivolumab for HCC may be contingent upon
clinical benefit being demonstrated in later-stage trials, according to
the press release. CheckMate 459,
a randomised phase 3 study comparing nivolumab to sorafenib for
first-line treatment of advanced HCC, is currently enrolling
Bristol-Myers Squibb has decided to delay seeking a European Union licence for the use of Opdivo for HCC until it has data from further clinical trials. A licensing application was withdrawn in July 2017
after the scientific committee of the EMA concluded that the lack of
data from studies comparing nivolumab to other therapies made it
impossible to determine whether the benefits of treatment with the drug
outweighed the risks.